CNS Pharmaceuticals, Inc. Adjustments to Additional Paid in Capital, Other
CNS Pharmaceuticals, Inc. (CNSP) reported Adjustments to Additional Paid in Capital, Other of -$14.17 thousand for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-14.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalOther · last filed 2025-11-14
- CNS Pharmaceuticals, Inc. adjustments to additional paid in capital, other for the quarter ending 2025-09-30 was -$14.17K.
| Period end | Adjustments to Additional Paid in Capital, Other 3 month |
|---|---|
| 2025-09-30 | -$14.17K 10-Q · filed 2025-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |